3-Tetrahydrofuran 4-methylphenylsulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Tetrahydrofuran 4-methylphenylsulfonate
• 英文别名: 4-Methyl-2-(oxolan-3-yl)benzenesulfonic acid
• 化学式: C₁₁H₁₄O₄S
• 分子量: 242.296
• InChiKey: WUZYZOHFKQLESZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羟基四氢呋喃 、 对甲苯磺酰氯 以 吡啶 为溶剂， 生成 3-Tetrahydrofuran 4-methylphenylsulfonate 、 tetrahydrofuran-3-yl 4-methylbenzenesulfonate
  参考文献：
  名称：

  Herbicidal 1-aryl-delta2-1,2,4-triazolin-5-ones

  摘要：

  阿瑞三唑啉酮的公式为##STR1##，其中W是氧或硫；X.sup.1和X.sup.2分别独立地选自卤素、卤代烷基和烷基；R是一个三到八个成员的环杂环基团，含有一个或两个相同或不同的环杂原子，选自氧、硫和氮，或者是一个带有上述杂环基团取代的烷基自由基；R.sup.1是烷基、卤代烷基、腈烷基、烯丙基、炔丙基或一个具有公式-烷基-Y--R.sup.3的基团；R.sup.2是卤素、烷基、腈烷基、卤代烷基、芳烷基或一个具有公式-烷基-Y--R.sup.3的基团；R.sup.3是烷基、烯丙基或炔丙基；Y是氧或S(O).sub.r，其中r是0到2，公开并举例说明了。

  公开号：

  US04702763A1

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018137573A1

  公开（公告）日：2018-08-02

  Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  提供的是抑制LRRK2激酶活性的新化合物，它们的制备过程，包含它们的组合物以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的用途，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof
  申请人：Emmennar Pharma Private Limited

  公开号：US20180346502A1

  公开（公告）日：2018-12-06

  The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.

  本发明涉及一种新颖的、改进的制备葡萄糖钠共转运蛋白2（SGLT-2）抑制剂及其新颖中间体的方法。更具体地说，本发明涉及一种新颖的、改进的用于制备格列列醇类化合物如恩帕格列醇和达帕格列醇及其中间体的方法。本发明的方法得到的产品可能是非晶态或结晶态，或者以非晶态/结晶态固体分散体/溶液的形式与药用可接受聚合物一起制备。此外，本发明得到的产品可用于制备用于预防和/或治疗与SGLT-2抑制相关的疾病和症状的药物。
• [EN] AMINOMETHYL-AZACYCLE DERIVATIVES AS INHIBITORS OF MONOAMINE UPTAKE<br/>[FR] DERIVES D'AMINOMETHYL-AZACYCLE INHIBITEURS D'ABSORPTION DE FIXATION DE MONOAMINE
  申请人：LILLY CO ELI

  公开号：WO2005118531A1

  公开（公告）日：2005-12-15

  The present invention provides compounds of formula (I) wherein A is (1), (2), (3), (4), (5), (6) or (7) and wherein R1, R7, y and Ar 1 are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of the central and/or peripheral nervous system.

  本发明提供了式（I）的化合物，其中A是（1）、（2）、（3）、（4）、（5）、（6）或（7），R1、R7、y和Ar 1在此处定义。这些化合物是选择自5-羟色胺、去甲肾上腺素和多巴胺中的一个或多个单胺的摄取抑制剂，因此可能在治疗中枢和/或外周神经系统疾病中有用。
• NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：ECKHARDT Matthias

  公开号：US20130252937A1

  公开（公告）日：2013-09-26

  The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 and m are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物， 其中基团R 1 ，R 2 和m如权利要求中所定义， 具有有价值的药理特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• PYRAZOLOTHIAZOLE COMPOUND
  申请人：SHIN Kogyoku

  公开号：US20110086882A1

  公开（公告）日：2011-04-14

  A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R 1 is -A 11 -A 12 ; A 11 is a single bond or a C1-6 alkylene group; A 12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R 2 is -A 21 -A 22 ; A 21 is a single bond or a C1-6 alkylene group; A 22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R 3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R 4 is a hydrogen atom or a C1-6 alkoxy group; R 5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R 6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R 7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group.

  化合物的分子式为(I)，或其药理学上可接受的盐，表现出优异的CRF受体拮抗作用，其中X是氮原子或CH；R1是-A11-A12；A11是一个单键或C1-6烷基链；A12是氢原子、C1-6烷基或C3-6环烷基等；R2是-A21-A22；A21是一个单键或C1-6烷基链；A22是氢原子、C1-6烷基、C3-6环烷基、非芳香杂环基或杂芳基等；R3是C1-6烷基、C3-6环烷基、C1-6烷氧基、C3-6环烷氧基C1-6烷基、二C1-6烷基氨基、卤素原子、氰基、甲酰基或羧基等；R4是氢原子或C1-6烷氧基；R5是卤素原子、C1-6烷基或C1-6烷氧基；R6是氢原子、C1-6烷基、C1-6烷氧基、C1-6烷基硫基或C1-6烷基亚砜基等；R7是C1-6烷基、C1-6烷氧基或C1-6烷基硫基。